Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.44% | 2.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.36% | -14.66% | |||
| Operating Income | 7.36% | 14.66% | |||
| Income Before Tax | 9.98% | -129.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.98% | -129.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.98% | -129.04% | |||
| EBIT | 7.36% | 14.66% | |||
| EBITDA | 7.51% | 14.68% | |||
| EPS Basic | 23.48% | -127.16% | |||
| Normalized Basic EPS | 86.15% | -249.67% | |||
| EPS Diluted | 23.48% | -130.00% | |||
| Normalized Diluted EPS | 86.15% | -253.20% | |||
| Average Basic Shares Outstanding | 16.73% | 7.38% | |||
| Average Diluted Shares Outstanding | 16.73% | 4.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||